Gosset 3 analyses
Investment AssessmentPsychiatryCNSNeurosciencePsychedelicsSmall molecule
DT120: off-patent LSD, reworked into a $4.4B psychiatry bet
Definium's single-dose lysergide posts a strong GAD Phase 2b and a positive MDD Phase 3, on a molecule off-patent since 1965. The moat, the ~39% modeled odds, and a bull rNPV that clears the $4.4B market cap all turn on one thing: whether the blind held.
Read analysis →